Shilan Mozafari

- shilan.mozafari@gmail.com, sh-mozafari@razi.tums.ac.ir
- ResearchGate, Linkedin, Google Scholar, ORCID

Academic Qualifications

Sep 2019–Oct 2024 **PhD Candidate**, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences (TUMS)

Sep 2004–Oct 2010 PharmD, TUMS

Professional Experiences

Oct 2024–Present Research Assistant, Pharmaceutical Sciences Research Center, TUMS

- Contributed to conducting systematic reviews and health economic evaluations by developing search strategies, selecting methodologies, extracting data, and drafting the manuscripts for publication.
- Collaborated with multidisciplinary teams across clinical, toxicology, epidemiology, and economic departments, contributing to health policy decisions.
- Contributed to research protocols and funding applications, ensuring compliance with ethical guidelines and institutional standards.
- Handled sensitive health and policy data with focus on confidentiality, secure data use, and equitable practices in research.
- Served as a peer reviewer for several international journals in the fields of health economics and evidence-based medicine.
- Mentored three PharmD thesis projects focused on pharmacoeconomics and health policy.

April 2014–July 2019 Medical advisor, National Drug Committee, IFDA

- Conducted systematic search of clinical guidelines and scientific literature to gather data on efficacy, safety, and cost-effectiveness of over 60 medicinal molecules.
- Synthesized evidence from multiple sources and integrated expert opinions to prepare robust reports supporting Health Technology Assessment (HTA) and reimbursement decisions.
- Assisted senior researchers in data extraction, quality appraisal, and critical assessment of clinical and economic studies.
- Supported the preparation of briefing documents and presentations for committee meetings and stakeholder discussions.
- Participated in workshops and training sessions to enhance knowledge of HTA methodologies, regulatory frameworks, and reimbursement policies.

Courses & Workshops

- Health Technology Assessment, Updates TUMS (May 2025)
- Systematic Review & Meta-analysis; a Hands-on Workshop on STATA, TUMS (Nov 2024)
- Budget Impact Analysis, The Third Euro-Asian Pharmacoepidemiology Congress (April 2020)

Shilan Mozafari

- Cost-effectiveness analysis alongside clinical trials, ISPOR (Sep 2014)
- Statistical considerations in health economic evaluation, ISPOR (Sep 2014)
- Network meta-analysis and indirect treatment comparisons, ISPOR (Sep 2014)
- Health economics for non-health economists, CELL for Pharma, Belgium (March 2014)

Teaching Experience

Lecturer, Pharmacology & Toxicology, Faculty of Pharmacy, TUMS | Oct 2019 – Present

Congress Presentations

Nov 2019	A systematic review of economic evaluations for pharmacogenetics tests of personalized
	medicines in gynecological cancer, Poster presentation, ISPOR, Denmark
	Pregnancy outcomes in women with inflammatory bowel disease following exposure to
Sep 2014	thiopurines and antitumor necrosis factor drugs, a systematic review with meta-analysis.
	Poster presentation, ISPOR, China

Selected Publications (Full list available on Google Scholar)

- Mozaffari S, Nosrati M, Sahraian MA, Yunesian M, Baeeri M, Abdollahi M, Nikfar S. The association between particulate matter exposure and the risk of multiple sclerosis incidence and relapses: A systematic review and meta-analysis of observational studies. 2025. Submitted for publication.
- Mozaffari S, Nosrati M, Sahraian MA, Yunesian M, Baeeri M, Abdollahi M, Nikfar S. Attributed medical cost of annual multiple sclerosis relapses in Iran related to exposure of ambient air particulate matter. *Pollution*. 2025.
- Nosrati M, **Mozaffari S**, Nikfar S. A systematic review of economic evaluations for pharmacogenetics tests of personalized medicines in gynecological cancers. *Value Health*. 2019.
- Zaboli P, Abdollahi M, **Mozaffari S**, Nikfar S. Tumor necrosis factor-alpha antibodies in fistulizing Crohn's disease: An updated systematic review and meta-analysis. *J Res Pharm Pract*. 2017;6(1):3–10.
- Didari T, **Mozaffari S**, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. *World J Gastroenterol*. 2015;21(10):3072–84.
- **Mozaffari S**, Abdolghaffari AH, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: A systematic review with meta-analysis. *Hum Exp Toxicol*. 2015;34(5):445–58.